ULTI Ultimovacs

Zelluna ASA [ZLNA]: Ex reverse share split today

Zelluna ASA [ZLNA]: Ex reverse share split today

Oslo, Norway, 1 April 2025

Issuer name: Zelluna ASA

Ex. date: 1 April 2025

Type of corporate action: Reverse share split

Other information:

Reverse split ratio – ten (10) old shares give one (1) new share.

New par value of NOK 1 per share

New ISIN is NO 001 3524942.

For further information, please contact:

Hans Vassgård Eid, CFO, Zelluna ASA

Email:

Phone:

About Zelluna ASA

Zelluna’s mission is to deliver transformative treatments with the capacity to cure advanced solid cancers, in a safe and cost-efficient manner, to patients on a global scale. The Company aims to do this by combining the most powerful elements of the immune system through pioneering the development of “off the shelf” T cell receptor (TCR) guided natural killer (NK) cell therapies (TCR-NK). The TCR-NK platform offers a unique mechanism of action with broad cancer detection capability to overcome the diversity of tumours and will be used “off the shelf” to overcome scaling limitations of current cell therapies. The lead program is a world’s first MAGE-A4 targeting “off the shelf” TCR-NK for the treatment of various solid cancers; a pipeline of earlier products follows. The Company is led by a management team of biotech entrepreneurs with deep experience in discovery through to clinical development of TCR and cell-based therapies including marketed products.



 



EN
01/04/2025

Underlying

ULTIUltimovacs

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Ultimovacs

 PRESS RELEASE
Free
ULTI ULTIMOVACS

Zelluna ASA [ZLNA]: Annual Report 2024

Zelluna ASA [ZLNA]: Annual Report 2024 Oslo, Norway, 02 April, 2025 - Zelluna ASA, a company pioneering allogeneic ‘off the shelf’ T Cell Receptor based Natural Killer (TCR-NK) cells for the treatment of cancer, announces that the Board of Directors of Zelluna ASA has approved the Annual Report for 2024.  Please find a PDF version of the annual report, as well as the report in European Single Electronic Format (ESEF), as attachments to this release. The Annual Report is also available at the company's website: This information is subject to the disclosure requirements pursuant to Section...

21h / 7m 1 EN
ABGSC Healthcare Research ... (+2)
  • ABGSC Healthcare Research
  • Alexander Krämer
04/01/25 April 1, 2025 1 EN
 PRESS RELEASE
Free
ULTI ULTIMOVACS

Zelluna ASA [ZLNA]: Ex reverse share split today

Zelluna ASA [ZLNA]: Ex reverse share split today Oslo, Norway, 1 April 2025 Issuer name: Zelluna ASAEx. date: 1 April 2025Type of corporate action: Reverse share split Other information:Reverse split ratio – ten (10) old shares give one (1) new share.New par value of NOK 1 per shareNew ISIN is NO 001 3524942. For further information, please contact: Hans Vassgård Eid, CFO, Zelluna ASAEmail: Phone: About Zelluna ASAZelluna’s mission is to deliver transformative treatments with the capacity to cure advanced solid cancers, in a safe and cost-efficient manner, to patients on a global sca...

April 1, 2025 1 EN
 PRESS RELEASE
Free
ULTI ULTIMOVACS

Zelluna ASA [ZLNA]: Registration of reverse share split

Zelluna ASA [ZLNA]: Registration of reverse share split Oslo, Norway, 31 March, 2025 Reference is made to the stock exchange notice published by the Zelluna ASA (the "Company") on 27 March 2025 with key information concerning a reverse share split in the ratio of 10:1. The reverse share split has today been registered with the Norwegian Register of Business Enterprises. After the registration of the reverse share split, the new number of outstanding shares in the Company is 20,227,066, each with a par value of NOK 1. For further information, please contact: Hans Vassgård Eid, CFO, Zellu...

March 31, 2025 1 EN
 PRESS RELEASE
Free
ULTI ULTIMOVACS

Zelluna ASA [ZLNA]: Key information regarding reverse share split and ...

Zelluna ASA [ZLNA]: Key information regarding reverse share split and change of ISIN Oslo, Norway, 27 March, 2025 Reference is made to the stock exchange notice published on 9 January 2025 regarding an extraordinary general meeting held in Zelluna ASA (the "Company"), where it was resolved to carry out a reverse share split in the ratio 10:1. Radforsk Investeringsstiftelse has further agreed with the Company to make available, without any compensation a, necessary number of its existing shares to the Company to ensure that all fractions of shares are rounded up to the nearest whole share...

March 27, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch